Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02507999
Other study ID # GDT
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 2015
Est. completion date February 2019

Study information

Verified date March 2019
Source Lawson Health Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Goal directed therapy (GDT) is a technique, which employs a non-invasive cardiac output monitoring (NICOM) device to guide management of circulating blood volume and blood pressure during procedures. The purpose of this study is to determine whether the use of goal-directed therapy to optimize blood volume and cardiac output during the procedure can improve the outcome of patients undergoing endovascular treatment of a brain aneurysm.


Description:

Subarachnoid hemorrhage (SAH) as a result of ruptured intracranial cerebral aneurysms is a life threatening condition; with an estimated incidence of 6-10 cases per 100,000 persons per year. Endovascular coil emobolization of the aneurysm is performed to isolate the aneurysm and reduce the risk of re-bleeding. Unfortunately, despite timely and successful intervention approximate 25% of post-coiling patients suffer immediate and/or long-term injury including death as a result of intracranial bleeding. This is mainly a consequence of subarachnoid hemorrhage-related complications , especially cerebral vasospasm. Angiographic vasospasm and symptomatic vasospasm occur in 30-70% and 20-30% of SAH patients respectively. Goal-directed therapy (GDT) provides a means to assess and manage circulating volume and cardiac output. In this study, the investigators would investigate the use of GDT during aneurysm coiling procedures can improve the clinical course of these patients.

This will be a blinded, randomized pilot study to compare clinical outcomes for endovascular coiling patients allocated to one of two treatments: GDT or non-GDT. Randomization consented patients will be randomized into GDT or non-GDT groups in 1:1 ratio. The attending anesthesiologists will not be blinded because of the nature of the intervention. However, surgeons, patients, outcomes assessors will be blinded as to the treatment intervention.

In all patients, an arterial catheter (routinely used in these patients) will be inserted and connected to the Flotrac (Edward Lifesciences). After transferring the patients into the angiogram suite, routine monitoring such as pulse oximetry, electrocardiography, non-invasive blood pressure monitoring, end-tidal CO2 and temperature probe will be attached to the patients. Anesthesia will be conducted in the standard fashion. Patients will be randomized into two groups in 1:1 ratio: GDT or non-GDT therapy.

- GDT group: the attending anesthesiologist will use the data obtained from the Flotrac to manage fluid and hemodynamics during the procedure following the prescribed treatment algorithm. The treatment interventions will start on induction of anesthesia and continue until the patients are extubated or transferred back to intensive care unit with mechanical ventilation.

- Non-GDT group: Flotrac will be connected but the machine values will be blinded to the anesthesiologist and interventionist. The screens of the Flotrac will be covered by opaque plastic bag and the alarms will be turned off. The attending anesthesiologist will make clinical decisions regarding the management of fluids and hemodynamics based on current individual routine practices.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date February 2019
Est. primary completion date February 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- All adult patients (age> 18 years of age) scheduled for aneurysm endovascular coiling procedures over the next 2 years.

- Grade I to IV SAH within 5 days of presentation will be included in the study.

- Only patients identified as appropriate by the neurosurgeon/neuro-radiologist will be recruited.

Exclusion Criteria:

- Patients with un-ruptured aneurysm(s)

- Patients with previous clipping or coiling procedure for the same aneurysm.

- Patients undergoing concomitant extracranial-intracranial bypass procedures or other non-neurosurgical procedures.

- Patients with giant aneurysm (size> 25mm)

- Pediatric patients (<18 years of age) or pregnant patients

- Unable to obtain informed consent from patients or substitute decision maker (SDM).

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Flotrac
Flotrac guided intervention

Locations

Country Name City State
Canada London Health Science Centre London Ontario

Sponsors (1)

Lead Sponsor Collaborator
Lawson Health Research Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Composite outcomes of cerebral vasospasm, stroke and death To determine if the use of the Flotrac device during surgery is able to decrease the morbidity and mortality rates for 30 days following surgery 30 days
Secondary Composite outcomes of all perioperative complications To assess the rate of occurrence of neurological and cardiopulmonary complications that may arise up to 90 days following the participant's surgical procedure. This will be assessed at 7 days, 30 days, and 90 days from the point of study entry. 7 days, 30 days, 90 days
Secondary Neurological outcomes Incidence of poor functional neurological outcomes at 7 days, 30 days and 90 days after the procedures. 7 days, 30 days, 90 days
Secondary Length of hospital stay Total length of stay in the neuro-critical care unit and in hospital. From study entry until hospital discharge, or up to 90 days of after the procedure
See also
  Status Clinical Trial Phase
Recruiting NCT04583163 - Variability in Transcranial Doppler Technique in Neuro-Critical Care Patients
Recruiting NCT03306836 - Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 2 N/A
Recruiting NCT03306823 - Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 1 N/A
Recruiting NCT02345395 - Safety Study of Minimally Invasive Approaches to Unruptured Anterior Circulation Aneurysms N/A
Completed NCT00962546 - Computed Tomographic (CT) Perfusion and CT Angiography as Screening Tools for Vasospasm Following Subarachnoid Hemorrhage N/A
Recruiting NCT04141020 - Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms Phase 2
Recruiting NCT01460563 - Valproic Acid, Magnesium Sulphate, Rocuronium Requirement, Postoperative Analgesia N/A
Recruiting NCT02162654 - Remote Ischemic Preconditioning for Intracranial Aneurysm Treatment N/A
Completed NCT01943591 - DELTA Trial: Does Embolization With Larger Coils Lead to Better Treatment of Aneurysms Trial N/A
Recruiting NCT03815149 - Safety and Clinical Effectiveness of Pipelineā„¢ Shield Devices for Intracranial Aneurysms
Completed NCT03152201 - New Findings About Somatosensory Evoked Potentials (SEP) During Surgery for Cerebral Aneurysms
Recruiting NCT02444832 - Multicenter Retrospective Registry of Anterior Communicating Artery Aneurysms With Endovascular Therapy N/A
Active, not recruiting NCT05774782 - Parent Artery Reconstruction for Cerebral Aneurysms Using a Novel Flow Diverter With Surface Modification N/A
Withdrawn NCT01878136 - Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage Phase 1/Phase 2
Withdrawn NCT02011321 - Clevidipine for Vasospasm After Subarachnoid Hemorrhage (SAH) Phase 2
Completed NCT02455440 - Esmolol Infusion in Patients Undergoing Craniotomy Phase 3
Completed NCT00614887 - Hypothalamo-, Pituitary-, Adrenal Axis Dysfunction in Subarachnoid Hemorrhage
Terminated NCT02281721 - Surpass Flow Diverter for Intracranial Aneurysms: SURMOUNT Registry Data Collection
Completed NCT04963933 - A Medical Device to Treat Brain Aneurysms N/A
Completed NCT02700607 - Impact of Intravascular Fluid Resuscitation and Whole Blood Viscosity N/A